What is claimed is:

1. A formulation comprising a concentrated protein in an amount greater than ~~about~~ 100 mg/mL and less than ~~about~~ 200 mg/mL, a tonicifier of a salt and a buffer present in a combined amount of ~~from about~~ 110 mM to ~~about~~ 120 mM and a surfactant, wherein the formulation ~~is hypotonic~~has an osmolality of less than 290 mOsm and has a viscosity of less than 40 cps.

2. The formulation of claim 1, wherein the concentrated protein is present in an amount of 162 mg/mL to 175 mg/mL.

3. The formulation of claim 1, wherein the concentrated protein is selected from a protein, a peptide, an enzyme, a polypeptide, an antibody, or a fragment of the antibody.

4. The formulation of claim 1, wherein the concentrated protein is a monoclonal antibody, a polyclonal antibody, a nanobody, a hybrid antibody, or a fragment thereof.

5. The formulation of claim 4, wherein the concentrated protein is a monoclonal antibody that is humanized or a fragment of the humanized antibody.

6. The formulation of claim 5, wherein the humanized antibody or fragment thereof is directed against one or more HIV polypeptides, one or more HCV polypeptides, or a cancer antigen.

7. The formulation of claim 1, wherein the salt is present in an amount of ~~about or equal to~~ 95 mM.

8. The formulation of claim 1, wherein the salt is present in an amount of ~~about or equal to~~ 90 mM.

9. The formulation of claim 1, wherein the salt is selected from ammonium chloride, ammonium sulfate, ammonium thiocyanate, arginine hydrochloride, calcium chloride, magnesium chloride , sodium acetate, sodium chloride, sodium gluconate, sodium lactate, sodium thiocyanate, zinc chloride, or any combination thereof.

10. The formulation of claim 9, wherein the salt is sodium chloride.

11. The formulation of claim 1, wherein the buffer is present in an amount of ~~about~~ 5 mM to ~~about~~ 20 mM.

12. The formulation of claim 11, wherein the buffer is present in an amount selected from 20 mM or 25 mM.

13. The formulation of claim 1, wherein the buffer is selected from one or more of an amino acid, an inorganic acid or an organic acid.

14. The formulation of claim 1, wherein the buffer comprises one or more amino acids, or a derivative or L-molecular form thereof.

15. The formulation of claim 14, wherein the one or more amino acids are histidine and/or glycine.

16. The formulation of claim 1, wherein the surfactant is present in an amount of ~~about or equal to~~ 0.001% w/v to ~~about or equal to~~ 0.2% w/v.

17. The formulation of claim 16, wherein the surfactant is present in an amount of ~~about~~ 0.005% w/v.

18. The formulation of claim 1, wherein the surfactant is selected from a detergent, pluronic, polysorbate, polyethylene glycol, or a combination thereof.

19. The formulation of claim 18, wherein the surfactant is selected from Pluronics® 188, polysorbate 20 (Tween® 20), polysorbate 80 (Tween® 80), or a combination thereof.

20. The formulation of claim 1, further comprising a stabilizing agent or a non-salt tonicifier.

21. The formulation of claim 20, wherein the stabilizing agent or non-salt tonicifier is present in an amount from ~~about~~ 0.05% w/v to ~~about~~ 1.8% w/v of the total formulation.

22. The formulation of claim 20, wherein the stabilizing agent or non-salt tonicifier is a sugar alcohol, a monosaccharide, a disaccharide, or a combination thereof.

23. The formulation of claim 22, wherein the stabilizing agent or non-salt tonicifier is selected from one or more of sorbitol, mannitol, sucrose, trehalose, glycerol, maltose, lactose, or a combination thereof.

24. The formulation of claim 1, wherein the formulation has a viscosity selected from 10 cps to ~~about~~ 25 cps ~~to about 60 cps~~ or 20 cps to ~~about~~ 30 cps ~~to about 50 cps~~.

25. The formulation of claim 1, wherein the formulation has a pH of ~~from about~~ 5.4 to ~~about~~ 6.4.

26. The formulation of claim 25, wherein the formulation has a pH of ~~from about~~ 5.4 to ~~about~~ 6.

27. The formulation of claim 25, wherein the formulation has a pH of 5.4 to 5.6.

~~28. The formulation of claim 1, wherein the formulation has an osmolality of less than about 290 mOs/kg.~~

~~29.~~28. The formulation of claim ~~28~~1, wherein the formulation has an osmolality of ~~about~~ 250 mOs/kg to ~~about~~ 280 mOs/kg.

~~30.~~29. The formulation of claim ~~29~~1, wherein the formulation has an osmolality of ~~about~~ 260 mOs/kg.

~~31.~~30. The formulation of claim 1, wherein the formulation comprises a therapeutic protein for subcutaneous administration to a subject in need thereof.

~~32.~~31. The formulation of claim ~~31~~30, wherein the therapeutic protein is administered via a syringe, a pen, a pump, a cartridge, a two-chambered cartridge, a multishot needle syringe, a multidose needle syringe, a multidose pen, a jet injector, a syrette, an autoinjector, or a pre-filled syringe.

~~33. The formulation of claim 1, wherein the formulation is in liquid or solution form.~~

~~34.~~32. A formulation comprising:

a concentrated protein in an amount greater than ~~about~~ 100 mg/mL and less than ~~about~~ 200 mg/mL;

a salt in an amount greater than ~~about~~ 90 mM and less than ~~about~~ 100 mM;

a buffer comprising a nonpolar neutral amino acid in an amount greater than ~~about~~ 5 mM and less than ~~about~~ 25 mM;

a surfactant in an amount greater than ~~about~~ 0.001 % w/v and less than ~~about~~ 0.2 % w/v; and, optionally,

a stabilizing agent or non-salt tonicifier in an amount of ~~about~~ 0.05% w/v to ~~about~~ 1.8% w/v; , wherein the formulation has an osmolality of ~~about 250~~ 222 to ~~about 280~~ 265 mOsm.

~~35.~~33. The formulation of claim ~~34~~32, wherein the concentrated protein is selected from an antibody or a fragment thereof, a blood clotting factor, an enzyme, a peptide, or a combination thereof.

~~36.~~34. The formulation of claim ~~34~~32, wherein the salt is selected from sodium chloride, sodium gluconate, sodium lactate, or a combination thereof.

~~37.~~35. The formulation of claim ~~34~~32, wherein the buffer ~~is selected from~~ includes a combination of glycine~~,~~ and histidine~~, or a combination thereof~~.

~~38. The formulation of claim 34, wherein the buffer is selected from succinic acid, maleic acid, tartaric acid, citric acid, acetic acid, or a combination thereof.~~

~~39.~~36. The formulation of claim ~~34~~32, wherein the surfactant is selected from polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-80, pluronic, or a combination thereof.

~~40.~~37. The formulation of claim ~~34~~32, wherein the stabilizing agent or non-salt tonicifier is selected from one or more of sorbitol, mannitol, sucrose, trehalose, glycerol, maltose, lactose, or a combination thereof.

~~41.~~38. The formulation of claim ~~34~~32, wherein the formulation has a viscosity ~~of~~ selected from 10 cps to ~~about~~ 25 cps ~~to about 60 cps~~ or 20 cps to 30 cps.

~~42.~~39. The formulation of claim ~~34~~32, wherein the formulation has a pH of ~~from~~ 5.4 – 6.4.

~~43.~~40. The formulation of claim ~~34~~32, wherein the formulation has an osmolality of ~~about~~ 240 mOs/kg ~~to about 280 mOs/kg~~.

~~44. The formulation of claim 34, wherein the formulation is a liquid or solution formulation.~~

~~45.~~41. A low viscosity, hypotonic formulation, comprising:

(a) a concentrated protein in an amount greater than 100 mg/mL and less than 200 mg/mL, wherein the concentrated protein is an antibody or a fragment thereof;

(b) a salt in an amount selected from 90 mM or 95 mM;

(c) a buffer comprising a neutral nonpolar amino acid and in an amount of 20 mM;

(d) a surfactant in an amount of 0.005% - 0.2% w/v; and optionally

(e) a stabilizing agent or non-salt tonicifier in an amount sufficient to provide an osmolality of ~~about 260-280~~ 222 to 265 mOs/kg, wherein the formulation has a viscosity of less than 40 cps.

~~46.~~42. The formulation of claim ~~45~~41, wherein the antibody is a monoclonal antibody or a humanized monoclonal antibody, or a fragment thereof; the salt is sodium chloride; the buffer is ~~glycine, histidine, or~~ a combination ~~thereof~~ of glycine and histidine; the surfactant is polysorbate; and the stabilizing agent or non-salt tonicifier is sorbitol.

~~47. The formulation of claim 45, wherein the formulation is a liquid or solution formulation.~~

~~48.~~43. A low viscosity hypotonic formulation, comprising:

(a) a concentrated antibody or fragment thereof in an amount greater than 100 mg/mL and less than 200 mg/mL, wherein the antibody is selected from a monoclonal antibody, a human antibody, or a humanized monoclonal antibody;

(b) a salt in an amount selected from 90 mM or 95 mM, wherein the salt is sodium chloride;

(c) a buffer in an amount of 20 mM, wherein the buffer comprises histidine, glycine, or a combination thereof;

(d) a surfactant in an amount of 0.005% - 0.2% w/v, wherein the surfactant is a polysorbate or poloxamer; and optionally,

(e) a stabilizing agent or non-salt tonicifier in an amount of 0.2% - 1.8% w/v, wherein the stabilizing agent or non-salt tonicifier is selected from a sugar alcohol, a monosaccharide, a disaccharide, or a combination thereof.

~~49.~~44. The formulation of claim ~~48~~43, wherein the stabilizing agent or non-salt tonicifier is selected from one or more of sorbitol, mannitol, sucrose, trehalose, glycerol, maltose, or lactose.

~~50. The formulation of claim 48, wherein the formulation is in liquid or solution form.~~

~~51.~~45. A low viscosity hypotonic formulation, comprising:

(a) a concentrated antibody or fragment thereof in an amount greater than ~~about~~ 100 mg/mL and less than ~~about~~ 200 mg/mL;

(b) a salt in an amount selected from ~~about~~ 90 mM or 95 mM, wherein the salt is selected from sodium chloride, sodium gluconate, or sodium lactate;

(c) a buffer in an amount of ~~about~~ 20 mM, wherein the buffer is selected from histidine, glycine, or a combination of histidine and glycine;

(d) a surfactant in an amount of ~~about~~ 0.005 % -0.2% w/v, wherein the surfactant is a polysorbate or a pluronic; and

(e) a stabilizing agent or non-salt tonicifier in an amount sufficient to provide an osmolality of the formulation of ~~about~~ 230 mOs/kg to ~~about~~ 280 mOs/kg, wherein the stabilizing agent or

non-salt tonicifier is selected from a sugar alcohol, a monosaccharide, a disaccharide, or a combination thereof.

~~52.~~46. The formulation of claim ~~51~~45, wherein the stabilizing agent or non-salt tonicifier is present in an amount of ~~about~~ 0.2% to 1.8% w/v.

~~53. The formulation of claim 51, wherein the formulation is in liquid or solution form.~~

~~54.~~47. A composition comprising a protein in an amount greater than 100 mg/mL and less than 200 mg/mL, a tonicifier comprising a salt and a buffer present in a combined amount of from 110 mM to 120 mM and a surfactant present in an amount of from 0.001% to ~~about~~ 0.2% w/v, wherein the formulation has an osmolality of ~~about~~ 230 to ~~about~~ 290 mOs/kg and the buffer includes a neutral nonpolar amino acid.

~~55.~~48. The composition of ~~claims 54~~claim 47, wherein the protein is an enzyme, a polypeptide, a peptide, an antibody or a fragment of an antibody.

~~56.~~49. The composition of claim ~~55~~48, wherein the antibody is a monoclonal antibody or a fragment thereof, a polyclonal antibody or a fragment thereof, a humanized monoclonal antibody or a fragment thereof, a human antibody or a fragment thereof, a nanobody, or a hybrid antibody or a fragment thereof.

~~57.~~50. The composition of claim 47~~5~~4, wherein the protein is present in an amount of 120 mg/mL to 185 m/mL.

~~58.~~51. The composition of claim 47~~5~~4, wherein the salt is present in an amount of 90 mM or 95 mM.

~~59.~~52. The composition of claim 47~~5~~4, wherein the buffer is present in an amount of 20 mM.

~~60.~~53. The composition of claim 47~~5~~4, wherein the surfactant is present in an amount of 0.005% w/v.

~~61.~~54. The composition of claim 47~~5~~4, further comprising a non-salt tonicifier in an amount of from 0.05% to 1.5% w/v.

~~62.~~55. The composition of claim 47~~5~~4 ~~or~~ claim ~~58~~ 51 wherein the salt is selected from one or more of sodium chloride, sodium gluconate, or sodium lactate.

~~63.~~56. The composition of claim 47~~5~~4 ~~or~~ claim ~~59~~52, wherein the buffer ~~is selected from one or more of~~ comprises ~~histidine or~~ glycine.

~~64.~~57. The composition of claim 47~~5~~4 ~~or~~ claim ~~60~~53, wherein the surfactant is selected from one or more of a polysorbate or a pluronic.

~~65.~~58. The composition of claim ~~64~~57, wherein the polysorbate is polysorbate 20 (Tween® 20) or polysorbate 80 (Tween® 80).

~~66.~~59. The composition of claim ~~61~~54, wherein the non-salt tonicifier is selected from one or more of sorbitol, mannitol, sucrose, trehalose, or glycerol.

~~67.~~60. The formulation or composition of any of claims ~~45~~41, ~~48~~43, ~~51~~45, or ~~54~~47, wherein the formulation has a viscosity of 15 cps to ~~about~~ 25 cps ~~to about 60 cps~~.

~~68.~~61. The formulation or composition of any of claims ~~45~~41, ~~48~~43, ~~51~~45, or ~~54~~47, wherein the formulation has a pH of ~~about~~ 5.4 to ~~about~~ 6.4.

~~69.~~62. The formulation of claim ~~68~~61, wherein the formulation has a pH of 5.4 to 5.6.

~~70.~~63. The formulation of any of claims 1, ~~34~~32, ~~45~~41, ~~48~~43, ~~51~~45, or ~~54~~47, wherein the formulation comprises a therapeutic protein for subcutaneous administration.

~~71.~~64. An article of manufacture comprising a container and a formulation having a viscosity of less than 40 cps comprising a protein in a concentration of greater than 100 mg/mL and less than 200 mg/mL, a tonicifier of a salt and a buffer present in a combined amount of from ~~about~~ 110 mM to ~~about~~ 120 mM, a surfactant in an amount of from ~~about~~ 0.005% to ~~about~~ 0.2% and instructions for use.

~~72.~~65. The article of manufacture of claim ~~71~~64, wherein the container is selected from a bottle, a vial, a syringe, a pen, a pump, a multidose needle syringe, a multidose pen, a jet injector, a syrette, an autoinjector, a pre-filled syringe, or a combination thereof.

~~73.~~66. The article of manufacture of claim ~~71~~64, wherein the formulation is included in the container.

67. The formulation of any of claims 32, 41, 45, or 47, wherein the salt is sodium chloride.

68. The formulation of any of claims 1, 43, or 45, wherein the buffer comprises a nonpolar neutral amino acid.

69. The formulation of any of claims 1, 32, 41, 43, 45, or 47, wherein the buffer comprises histidine, a derivative or L-molecular form of histidine, or a combination of histidine and a derivative or L-molecular form of histidine, in an amount of 5 mM.

70. The formulation of any of claims 1, 32, 41, 43, 45, or 47, wherein the buffer comprises glycine in an amount of 15 mM.

71. The formulation of claim 69, wherein the buffer further comprises glycine in an amount of 15 mM.

72. The formulation of any of claims 32, 41, 43, or 45, further comprising a surfactant in an amount of 0.005% w/v.

73. The formulation of claim 72, wherein the surfactant is polysorbate 20 (Tween® 20).

74. The formulation of any of claims 1, 32, 41, 43, 45, or 47, further comprising a stabilizing agent or non-salt tonicifier in an amount of 0.3% w/v of the total formulation.

75. The formulation of claim 74, wherein the stabilizing agent or non-salt tonicifier is sorbitol.

76. The formulation of any of claims 1, 43, 45, or 47, wherein the formulation has an osmolality of 222 to 265 mOs/kg.

77. The formulation of any of claims 1, 32, 41, 45, 45, or 47, wherein the formulation has a viscosity of 15 cps.

78. The formulation of any of claims 1, 32, 41, 43, 45, or 47, wherein the formulation is manipulable through a 25 g to 27 g syringe needle.

79. The formulation of any of claims 1, 32, 41, 43, 45, or 47, wherein the formulation has a pH between 5.4 and 5.5.

80. The formulation of any of claims 1, 32, 41, 43, 45, or 47, wherein the formulation is stable for at least 12 months at a temperature ranging from 2°C to 8°C.